Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831

Patrick C. Roche, Vera Jean Suman, Robert Brian Jenkins, Nancy E. Davidson, Silvana Martino, Peter A. Kaufman, Ferdinand K. Addo, Bronagh Murphy, James N. Ingle, Edith A. Perez

Research output: Contribution to journalArticle

338 Citations (Scopus)

Abstract

The efficacy of trastuzumab for metastases coupled with the relatively poor prognosis of patients with node-positive, HER2-positive breast cancer has led to the evaluation of trastuzumab as an adjuvant therapy. A prospective, randomized, three-arm, phase III trial is being conducted by the Breast Intergroup (N9831) for women with primary, operable, histologically confirmed, node-positive breast carcinoma that strongly over-expresses (3+) HER2 protein and/or displays HER2/neu gene amplification, as determined by local laboratory testing. The protocol requires confirmatory central testing of HER2 status using the HercepTest™ immunohistochemistry and the Vysis PathVysion™ fluorescence in situ hybridization (FISH) assays. Tumor specimens from the first 119 patients enrolled in N9831 were centrally tested; 74% were found to be HercepTest™ 3+ and 66% were found to have HER2 gene amplification. Only six of nine (67%) of the specimens submitted by local laboratories as FISH positive could be confirmed by central assays. The concordance for central HercepTest™ and central FISH assays was 92%. The poor concordance (74%) between local and central testing for HER2 status has led to modifications in the eligibility criteria for N9831.

Original languageEnglish (US)
Pages (from-to)855-857
Number of pages3
JournalJournal of the National Cancer Institute
Volume94
Issue number11
StatePublished - Jun 5 2002

Fingerprint

erbB-2 Genes
Fluorescence In Situ Hybridization
Breast
Gene Amplification
Breast Neoplasms
Arm
Immunohistochemistry
Neoplasm Metastasis
Neoplasms
Proteins
Trastuzumab
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. / Roche, Patrick C.; Suman, Vera Jean; Jenkins, Robert Brian; Davidson, Nancy E.; Martino, Silvana; Kaufman, Peter A.; Addo, Ferdinand K.; Murphy, Bronagh; Ingle, James N.; Perez, Edith A.

In: Journal of the National Cancer Institute, Vol. 94, No. 11, 05.06.2002, p. 855-857.

Research output: Contribution to journalArticle

Roche, PC, Suman, VJ, Jenkins, RB, Davidson, NE, Martino, S, Kaufman, PA, Addo, FK, Murphy, B, Ingle, JN & Perez, EA 2002, 'Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831', Journal of the National Cancer Institute, vol. 94, no. 11, pp. 855-857.
Roche, Patrick C. ; Suman, Vera Jean ; Jenkins, Robert Brian ; Davidson, Nancy E. ; Martino, Silvana ; Kaufman, Peter A. ; Addo, Ferdinand K. ; Murphy, Bronagh ; Ingle, James N. ; Perez, Edith A. / Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. In: Journal of the National Cancer Institute. 2002 ; Vol. 94, No. 11. pp. 855-857.
@article{8fb3167eb8bf4bbba1387136a1933382,
title = "Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831",
abstract = "The efficacy of trastuzumab for metastases coupled with the relatively poor prognosis of patients with node-positive, HER2-positive breast cancer has led to the evaluation of trastuzumab as an adjuvant therapy. A prospective, randomized, three-arm, phase III trial is being conducted by the Breast Intergroup (N9831) for women with primary, operable, histologically confirmed, node-positive breast carcinoma that strongly over-expresses (3+) HER2 protein and/or displays HER2/neu gene amplification, as determined by local laboratory testing. The protocol requires confirmatory central testing of HER2 status using the HercepTest™ immunohistochemistry and the Vysis PathVysion™ fluorescence in situ hybridization (FISH) assays. Tumor specimens from the first 119 patients enrolled in N9831 were centrally tested; 74{\%} were found to be HercepTest™ 3+ and 66{\%} were found to have HER2 gene amplification. Only six of nine (67{\%}) of the specimens submitted by local laboratories as FISH positive could be confirmed by central assays. The concordance for central HercepTest™ and central FISH assays was 92{\%}. The poor concordance (74{\%}) between local and central testing for HER2 status has led to modifications in the eligibility criteria for N9831.",
author = "Roche, {Patrick C.} and Suman, {Vera Jean} and Jenkins, {Robert Brian} and Davidson, {Nancy E.} and Silvana Martino and Kaufman, {Peter A.} and Addo, {Ferdinand K.} and Bronagh Murphy and Ingle, {James N.} and Perez, {Edith A.}",
year = "2002",
month = "6",
day = "5",
language = "English (US)",
volume = "94",
pages = "855--857",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831

AU - Roche, Patrick C.

AU - Suman, Vera Jean

AU - Jenkins, Robert Brian

AU - Davidson, Nancy E.

AU - Martino, Silvana

AU - Kaufman, Peter A.

AU - Addo, Ferdinand K.

AU - Murphy, Bronagh

AU - Ingle, James N.

AU - Perez, Edith A.

PY - 2002/6/5

Y1 - 2002/6/5

N2 - The efficacy of trastuzumab for metastases coupled with the relatively poor prognosis of patients with node-positive, HER2-positive breast cancer has led to the evaluation of trastuzumab as an adjuvant therapy. A prospective, randomized, three-arm, phase III trial is being conducted by the Breast Intergroup (N9831) for women with primary, operable, histologically confirmed, node-positive breast carcinoma that strongly over-expresses (3+) HER2 protein and/or displays HER2/neu gene amplification, as determined by local laboratory testing. The protocol requires confirmatory central testing of HER2 status using the HercepTest™ immunohistochemistry and the Vysis PathVysion™ fluorescence in situ hybridization (FISH) assays. Tumor specimens from the first 119 patients enrolled in N9831 were centrally tested; 74% were found to be HercepTest™ 3+ and 66% were found to have HER2 gene amplification. Only six of nine (67%) of the specimens submitted by local laboratories as FISH positive could be confirmed by central assays. The concordance for central HercepTest™ and central FISH assays was 92%. The poor concordance (74%) between local and central testing for HER2 status has led to modifications in the eligibility criteria for N9831.

AB - The efficacy of trastuzumab for metastases coupled with the relatively poor prognosis of patients with node-positive, HER2-positive breast cancer has led to the evaluation of trastuzumab as an adjuvant therapy. A prospective, randomized, three-arm, phase III trial is being conducted by the Breast Intergroup (N9831) for women with primary, operable, histologically confirmed, node-positive breast carcinoma that strongly over-expresses (3+) HER2 protein and/or displays HER2/neu gene amplification, as determined by local laboratory testing. The protocol requires confirmatory central testing of HER2 status using the HercepTest™ immunohistochemistry and the Vysis PathVysion™ fluorescence in situ hybridization (FISH) assays. Tumor specimens from the first 119 patients enrolled in N9831 were centrally tested; 74% were found to be HercepTest™ 3+ and 66% were found to have HER2 gene amplification. Only six of nine (67%) of the specimens submitted by local laboratories as FISH positive could be confirmed by central assays. The concordance for central HercepTest™ and central FISH assays was 92%. The poor concordance (74%) between local and central testing for HER2 status has led to modifications in the eligibility criteria for N9831.

UR - http://www.scopus.com/inward/record.url?scp=0037024478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037024478&partnerID=8YFLogxK

M3 - Article

C2 - 12048274

AN - SCOPUS:0037024478

VL - 94

SP - 855

EP - 857

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 11

ER -